Ascentage Pharma Group International (NASDAQ:AAPG) Trading 20.3% Higher – Here’s Why

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) traded up 20.3% on Wednesday . The stock traded as high as $23.00 and last traded at $22.9850. 202 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 3,402 shares. The stock had previously closed at $19.11.

Analysts Set New Price Targets

AAPG has been the topic of several recent analyst reports. Oppenheimer assumed coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective on the stock. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Thursday. Finally, Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The firm has a fifty day simple moving average of $24.10 and a two-hundred day simple moving average of $29.99.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million during the quarter.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently made changes to their positions in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $96,000. ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International in the third quarter worth about $204,000. Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International during the third quarter worth approximately $383,000. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International during the second quarter worth approximately $391,000. Finally, Tema Etfs LLC purchased a new stake in Ascentage Pharma Group International during the second quarter valued at approximately $610,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.